BIOMÉRIEUX |
Market Closed -
Other stock markets
|
After market 03:08:59 pm | |||
| 99.5 EUR | -1.19% |
|
99.85 | +0.35% |
| Apr. 23 | Deutsche Bank Initiates BioMérieux Coverage at Purchase | MT |
| Apr. 23 | BIOMÉRIEUX : Deutsche Bank initiates buy coverage | CF |
| Sales 2024 * | 3.9B 4.18B | Sales 2025 * | 4.19B 4.5B | Capitalization | 11.9B 12.75B |
|---|---|---|---|---|---|
| Net income 2024 * | 466M 499M | Net income 2025 * | 528M 566M | EV / Sales 2024 * | 2.97 x |
| Net cash position 2024 * | 307M 329M | Net cash position 2025 * | 489M 525M | EV / Sales 2025 * | 2.72 x |
| P/E ratio 2024 * |
26.1
x | P/E ratio 2025 * |
23
x | Employees | 13,696 |
| Yield 2024 * |
0.86% | Yield 2025 * |
1% | Free-Float | 35.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More press releases
More news
| 1 day | -0.79% | ||
| 1 week | +0.91% | ||
| Current month | -2.30% | ||
| 1 month | -0.70% | ||
| 3 months | -4.13% | ||
| 6 months | +13.94% | ||
| Current year | -0.70% |
1 week
97.20
102.90
1 month
94.60108.90
Current year
94.26108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
| Chairman | 50 | 04-04-15 | |
| Director of Finance/CFO | 47 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 06-09-14 | |
| Director/Board Member | 63 | 04-12-31 | |
| Chairman | 50 | 04-04-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 16 M€ | -7.62% | ||
| 0.26% | 1,120 M€ | +0.38% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 99.5 | -1.19% | 60 768 |
| 24-04-24 | 100.7 | -0.69% | 97,428 |
| 24-04-23 | 101.4 | +0.70% | 85,555 |
| 24-04-22 | 100.7 | +1.16% | 63,133 |
| 24-04-19 | 99.55 | +0.56% | 90,955 |
Real-time Euronext Paris, April 25, 2024 at 04:04 am EDT
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-05-22
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
100.7
EUR
Average target price
112.2
EUR
Spread / Average Target
+11.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.70% | 12.72B | |
| -11.57% | 7.5B | |
| +2.64% | 5.48B | |
| +0.98% | 4.61B | |
| +5.18% | 4.47B | |
| -50.82% | 3.28B | |
| +11.23% | 2.71B | |
| -15.46% | 2.02B | |
| -2.66% | 1.69B | |
| -10.84% | 1.74B |
- Stock Market
- Equities
- BIM Stock
